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The combination of relative nutrient deprivation and dysregulation of protein synthesis make malignant cells
especially prone to protein misfolding. Endoplasmic reticulum stress, which results from protein misfolding
within the secretory pathway, has a profound effect on cancer cell proliferation and survival. In this review, we
examine the evidence implicating endoplasmic reticulum dysfunction in the pathology of cancer and discuss
how recent findings may help to identify novel therapeutic targets.In the crowded molecular environment of the endoplasmic retic-
ulum (ER), protein maturation requires the coordinated activity of
many chaperones and folding enzymes. BiP is an abundant ER
HSP70 chaperone that binds to exposed stretches of hydro-
phobic residues of immature polypeptide chains, while GRP94
is an HSP90 chaperone involved in subsequent folding steps
for a subset of ER client proteins. When the efficiency of secre-
tory protein folding is threatened, the cell is said to experience
‘‘ER stress’’ and elicits a homeostatic ‘‘unfolded protein
response’’ (UPR) (Figure 1) (Walter and Ron, 2011). The diverse
substrate repertoire of BiP enables it to function as a master
regulator of the UPR by binding to and inactivating the three
ER stress sensors, PERK, IRE1, and ATF6. During ER stress,
increased levels of unfolded substrates lead to the sequestration
of BiP, freeing the sensors to initiate UPR signaling. PERK
ameliorates ER stress through phosphorylation of the translation
initiation factor eIF2a. This causes generalized attenuation of
protein synthesis while also promoting the translation of a subset
of UPR target proteins, including the transcription factor ATF4.
ATF4 induces expression of the transcription factor CHOP and,
subsequently, the phosphatase subunit GADD34, which specif-
ically dephosphorylates eIF2a, enabling the recovery of protein
translation (Marciniak et al., 2004). The induction of ER oxidase
1a (ERO1a) by CHOP promotes oxidative protein folding in the
ER, but this increased formation of disulphide bonds can
contribute to worsening cellular stress through the generation
of reactive oxygen species (ROS). However, additional targets
of ATF4 include enzymes necessary to withstand oxidative
stress, which tend to limit this toxicity. Additional targets of
ATF4 promote amino acid import and synthesis, thus playing a
cytoprotective role during a variety of stressful insults. Because
other eIF2a kinases responding to different stresses can trigger
this pathway—for example, GCN2 responds to amino acid
deprivation—it has been named the integrated stress response
(ISR; Figure 2) (Harding et al., 2003).
Tumor Growth
As solid cancers grow, their nutrient requirements eventually
exceed the capacity of the existing vascular bed. Although
many cancers adapt by triggering angiogenesis, inevitably the
cores of most tumors become hypoxic and nutrient depleted.
Impaired generation of ATP compromises ER protein folding,
thus leading to activation of the UPR and ISR, while aminoacid starvation further contributes to ISR activation. Indeed,
phosphorylation of eIF2a by PERK has been shown to be neces-
sary for the growth of larger solid tumors (Bi et al., 2005).
During hypoxia, generation of ROS increases both in mito-
chondria (Brunelle et al., 2005) and the ER, partly through
UPR-mediated induction of ERO1a (Marciniak et al., 2004;
Song et al., 2008). Accordingly, a key function of the ISR is to
defend against oxidative stress, primarily by increasing biosyn-
thesis of the antioxidant glutathione (Harding et al., 2003). The
resulting increased capacity for oxidative protein folding is bene-
ficial for tumor growth. Levels of ERO1a correlate with a worse
prognosis in breast cancer (Kutomi et al., 2013), and depleting
breast carcinoma cells of PERK increases ROS production and
impairs cell growth (Bobrovnikova-Marjon et al., 2010). More-
over, the loss of PERK promotes G2/M cell cycle delay due to
oxidative damage of DNA (Bobrovnikova-Marjon et al., 2010).
This PERK-mediated resistance to oxidative stress is also
implicated in resistance to radiotherapy (Rouschop et al.,
2013; Rouschop et al., 2010), an effect of tumor adaptation to
preconditioned ER stress.
In addition to the ATF4-dependent antioxidant response, cells
can induce antioxidant pathways via Nrf2. This transcription fac-
tor is normally held inactive within the cytosol through binding to
Keap1, which promotes its ubiquitination by Cul3 and subse-
quent proteasomal degradation. Upon oxidative stress, Keap1
releases Nrf2 to transactivate target genes within the nucleus.
It has been suggested that this interaction is modulated by
PERK. Two early reports suggested that Nrf2 could be phos-
phorylated by PERK during ER stress, triggering dissociation
from Keap1 and induction of antioxidant genes (Cullinan and
Diehl, 2004; Cullinan et al., 2003). Indeed, Nrf2 appears to be
beneficial during ER stress-induced oxidative stress. However,
activation of PERK’s kinase domain in the absence of ER stress
leads to induction of ISR target genes in a manner that is entirely
dependent on phosphorylation of eIF2a (Lu et al., 2004). This
suggests either that phosphorylation of Nrf2 plays a minor role
in the transcriptional response to ER stress or that it is important
only when additional arms of the UPR are active.
Recent observations suggest that activation of the UPR in
hypoxic tumors leads to increased autophagy (Rouschop
et al., 2010). Autophagy is cytoprotective during stress by liber-
ating amino acids from long-lived proteins and the removal of
damaged organelles. Accordingly, hypoxic regions of humanCancer Cell 25, May 12, 2014 ª2014 Elsevier Inc. 563
Figure 1. The UPR
Nascent secretory proteins synthesized by ER-
bound ribosomes enter the ER lumen. When the
load of unfolded protein threatens to exceed the
capacity of the organelle to fold them, the cell is
said to experience ER stress. This triggers three
UPR signal transducers: PERK, IRE1, and ATF6.
Activated PERK dimerizes, autophosphorylates,
and then phosphorylates the translation initiation
factor subunit eIF2a, causing general attenuation
of translation that lessens ER protein client load
while also increasing the translation of a subset of
genes, including the transcription factor ATF4.
Activated IRE1 oligomerizes, triggering its endo-
nuclease activity to initiate splicing of XBP1mRNA
and synthesis of the UPR transcription factor
XBP1s. Activated IRE1 can also degrade a variety
of mRNAs in proximity to the ER to reduced ER
client protein load; a process termed regulated
IRE1-dependent decay (RIDD). ATF6 traffics from
the ER to the Golgi apparatus during stress and is
cleaved to release a soluble UPR transcription
factor, ATF6c.
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autophagy factors, such as LC3, and increased autophagy. In
multiple cell lines, PERK mediates the upregulation of LC3 and
autophagy-related gene 5 via ATF4 and CHOP, respectively,
promoting phagophore formation (Rouschop et al., 2010). The
inability of PERK-deficient cells to replenish LC3 correlates
with impaired survival when subjected to hypoxia. Although
PERK clearly plays an important role in the survival of hypoxic
tumor cells, the IRE1 arm of the UPR is also important. During
hypoxia-induced ER stress, IRE1-driven XBP1 splicing (to
generate XBP1s) increases tumor cell tolerance to hypoxia,
whereas loss of XBP1 impairs hypoxic tumor growth (Romero-
Ramirez et al., 2004). Indeed, in breast cancer, increased
splicing of XBP1 is associated with a worse prognosis, perhaps
reflecting an increased tolerance of tumor cells to hypoxia
(Davies et al., 2008).
Angiogenesis and Invasion
It is well established that tumor hypoxia and glucose deprivation
induce angiogenesis. Hypoxia achieves this via HIF, but the
mechanism of nutrient limitation has remained obscure until
recently. Evidence suggests that the PERK-ATF4 arm of the
UPR directly upregulates vascular endothelial growth factor
(VEGF) while downregulating inhibitors of angiogenesis (Blais
et al., 2006; Wang et al., 2012). Depleting cells of PERK prevents
upregulation of VEGF by glucose deprivation, whereas antago-
nism of HIF1a does not (Wang et al., 2012). Similarly, inhibition564 Cancer Cell 25, May 12, 2014 ª2014 Elsevier Inc.of PERK, which reduces the growth of
xenograft tumors in mice, decreases
tumor vascularity and perfusion (Wang
et al., 2012). In addition, hypoxia-induced
vascularization is modulated by IRE1a
(Drogat et al., 2007). Ire1a/ mouse em-
bryonic fibroblasts and glioblastoma cells
expressing dominant-negative IRE1a
induce less VEGFA in ischemic condi-
tions, limiting growth and angiogenesis
of xenografts. In a human gliomamodel, it has been demonstrated that IRE1a is involved in
the expression of angiogenic factors, including VEGFA and
interleukin-6 (IL6), while suppressing the expression of antian-
giogenic factors (Auf et al., 2010). Consequently, loss of IRE1a
impairs glioma growth with increased overall survival of
glioma-implanted animals. However, the relationship between
IRE1a signaling and angiogenesis appears to be complex since,
in nonmalignant models of ischemia, IRE1 has been shown to
impair vascular regeneration by degrading mRNA encoding
the neurovascular guidance cue netrin-1 via the process of regu-
lated IRE1 dependent decay (RIDD) (Binet et al., 2013).
It is surprising that, although antagonism of IRE1 can impair
tumor vascularity and improve survival, it may promote tumor
invasion (Auf et al., 2010). Hypovascularity may contribute to
invasiveness, but a more complex picture is likely, as the induc-
tion of angiogensis does not fully suppress the infiltrative proper-
ties of IRE1-deficient glioma cells. Recent analysis has revealed
that the increased migratory phenotype likely reflects changes in
the secretome via a reduction in RIDD (Dejeans et al., 2012b). For
example, antagonism of IRE1 increases levels of the RIDD
target BM-40, promoting cell adhesion and migration (Dejeans
et al., 2012b). This suggests that, while suppression of IRE1
signalingmay offer a novel approach to target tumor vasculariza-
tion, it also risks promoting tumor invasion and so deserves
further study.
Tumor invasion is also influenced by epithelial-to-mesen-
chymal transition (EMT), a known characteristic of ER-stressed
Figure 2. The ISR
Phosphorylation of eIF2a serves as a hub for
integration of signals mediated by a family of
kinases: PERK responds to ER stress, HRI re-
sponds to iron deficiency and to oxidative stress,
PKR is activated by dsRNA during some viral in-
fections, and GCN2 is activated during amino acid
starvation (Harding et al., 2003). In unstressed
conditions, eIF2a supports new protein synthesis
as a component of the eIF2 complex that recruits
initiator methionyl-tRNA to the ribosome. During
its catalytic cycle, the eIF2 complex hydrolyzes
bound GTP and must interact with the guanine
nucleotide exchange factor eIF2B to be recharged
with GTP. Once eIF2a is phosphorylated, it
becomes a potent antagonist of eIF2B and thus
attenuates the rate of protein translation. Low
basal levels of eIF2a phosphorylation are antago-
nized by the constitutively expressed eIF2a
phosphatase CReP, but during stress, this is
overwhelmed and phospho-eIF2a accumulates.
While translation of most mRNAs is reduced by
phosphorylation of eIF2a, a subset is translated
more efficiently, most notably, the transcript factor
ATF4. This transactivates most genes of the ISR,
including amino acid transporters and synthe-
tases, which help counter amino acid limitation
while providing the thiol moieties necessary for
synthesis of the antioxidant glutathione. Subse-
quently, ATF4 induces another transcription factor
CHOP, which induces the eIF2a phosphatase GADD34 leading to dephosphorylation of eIF2a and the resumption of normal rates of cap-dependent translation.
CHOP also induces the ER oxidase ERO1a, thus promoting oxidative protein folding. While the induction of GADD34 and ERO1a can be seen as adaptive during
the response to transient ER stress, their induction during chronic stressful circumstances can contributes to worsening stress and result in exaggerated toxicity.
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and Notch signaling link hypoxia with EMT, causing loss of
epithelial integrity through downregulation of adhesion mole-
cules such as E-cadherin (Lester et al., 2007; Sahlgren et al.,
2008). Simultaneously, increased chemotaxis accompanies the
induction of the chemokine receptor CXCR4 (Azab et al., 2012;
Barriga et al., 2013). Thus, EMT promotes metastasis by
removing impediments to the egress of cells from their original
tumor while also honing them to new niches (reviewed in Hana-
han and Weinberg, 2011). ER stress has been shown to drive
EMT in vitro and in animal models of fibrosis through src-
mediated signaling (Tanjore et al., 2011; Ulianich et al., 2008).
It is therefore plausible that ER stress may contribute to EMT in
cancer invasion, although more formal examinations of this are
needed. A further consideration is that phenotypic change
from epithelium to mesenchyme will affect the secretory capac-
ity of a cell, thus altering its vulnerability to ER stress. Consistent
with this, evidence suggests that expression of the ER stress
markers CHOP and GADD34 change during dedifferentiation
of mesothelioma cells (Dalton et al., 2013).
ER-Mitochondrial Communication
Through a proteostatic network, impaired protein folding in one
cellular location leads to the propagation of cell-wide responses.
The interplay between the mitochondrial HSP90 chaperone net-
works and the protein-folding environment of the ER exemplifies
such a mechanism. HSP90 and its related chaperone, TRAP-1,
are abundant in the mitochondria of tumor cells but not in those
of most normal tissues, and they appear to antagonize mito-
chondrial death pathways (Chae et al., 2012). It is not surprising
that impaired function of mitochondrial HSP90 leads to a mito-
chondrial UPR and the induction of autophagy (Siegelin et al.,2011). More recently, it has been shown that inhibition of mito-
chondrial HSP90 using the small molecule gamitrinib disrupts
tumor bioenergetics to such an extent that ER stress pathways
are activated (Chae et al., 2012). Notably, activation of the clas-
sical UPR of the ER was necessary for survival of mitochondrial
proteotoxicity.
Direct communication between the mitochondrion and ER
during stress serves to modulate the function of both organ-
elles. PERK is enriched at mitochondrial-ER contact sites
and appears to tether mitochondria to the ER membrane
(Figure 3) (Verfaillie et al., 2012). Mitofusin 2 (Mfn2), a GTPase
of the mitochondrial outer membrane that mediates mitochon-
drial fusion, has recently been shown to bind directly to PERK
(Mun˜oz et al., 2013). Because cells lacking Mfn2 experience
basal activation of PERK, it has been suggested that Mfn2
may normally inhibit PERK signaling. However, enhanced
signaling in all three branches of the UPR in Mfn2/ cells is
difficult to explain by this dysinhibition of PERK alone, since
exaggerated phosphorylation of eIF2a would reduce ER stress
by attenuating protein translation. It therefore seems likely that
ER-mitochondrial signaling is affected more extensively.
Indeed, PERK modulates mitochondrial morphology and func-
tion, with overexpression of PERK causing mitochondrial frag-
mentation and reduced respiration, while depletion of PERK
reduces mitochondrial calcium overload and ROS production
in Mfn2-deficient cells (Mun˜oz et al., 2013). It is interesting
that the tethering function of PERK appears independent
of its kinase activity and facilitates ROS-mediated proapop-
totic signaling between the ER and mitochondrion (Verfaillie
et al., 2012). These organelles therefore function in tandem
and can both contribute to oxidative stress through production
of ROS.Cancer Cell 25, May 12, 2014 ª2014 Elsevier Inc. 565
Figure 3. ER-Mitochondrial Communication during ER Stress
During ER stress, IRE1mediates activation of c-Jun N-terminal kinase (JNK) and apoptosis via activation of pro-apoptotic BH3 only family Bcl-2 proteins, such as
Bid, and inhibition of anti-apoptotic Bcl-2 (reviewed in Tabas and Ron, 2011). Calcium released from the ER is taken up by the mitochondrion to stimulate the
production of ROS and the release of cytochrome c, both of which promote apoptosis. Prolonged PERK activation induces ERO1a leading to increased pro-
duction of ROS within the ER. Mfn2, which along with mitofusin 1 (Mfn1) tethers mitochondria to the ER membrane (de Brito and Scorrano, 2008), is thought to
inhibit PERK by direct interaction. Ablation of Mfn2 leads to gross mitochondrial dysfunction in a PERK dependent manner, suggesting the existence of further,
yet to be discovered, interactions.
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In addition to communication between organelles during failure
of proteostasis, it has been suggested that, in cancer, ER
stress signals may be transmissible from cell to cell. One pro-
posed mechanism involves the tumor suppressor PAWR, which
is known to promote prostate cancer cell apoptosis via WT1.
Brief exposure to ER stress causes the secretion of PAWR
into the extracellular space that can trigger the apoptosis of
nearby cancer cells (Burikhanov et al., 2009). Controversially,
the ‘‘receptor’’ on nearby cells has been reported to be the
chaperone BiP (Burikhanov et al., 2009), and it has been sug-
gested that ER stress induces surface presentation of ER
chaperones that can then modulate the activity of other plasma
membrane proteins, such as cripto (Kelber et al., 2009). The566 Cancer Cell 25, May 12, 2014 ª2014 Elsevier Inc.apparent surface translocation of ER chaperones in cancer
cells must be subjected to further rigorous validation and would
be greatly strengthened by further mechanistic insight. How-
ever, the observation that cripto-dependent SMAD signaling
can be blocked by an antibody recognizing surface-exposed
BiP raises the possibility that this putative cancer-cell-specific
mechanism may offer novel therapeutic targets (Kelber et al.,
2009).
Cancer Cell Death
Depending on the context of ER stress, including intensity and
duration, the UPR can promote survival or trigger cell death. In
B cell chronic lymphocytic lymphoma, ER stress has been impli-
cated in causing spontaneous tumor cell apoptosis (Rosati et al.,
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partially redundant parallel pathways (reviewed in Tabas and
Ron, 2011), but evidence implicates PERK as a major effector
(Marciniak et al., 2004). Because loss of CHOP, a downstream
target of PERK, renders cells and mice more resistant to ER
stress, for some time it was believed that CHOP regulates a
cell death program, a theory that was not supported by tran-
scriptional analysis (Han et al., 2013; Marciniak et al., 2004).
Instead, CHOP regulates a complex array of more than 200
genes, which promote ongoing protein secretion and autophagy
(Marciniak et al., 2004; Rouschop et al., 2010). For example, by
inducing the ISR targets GADD34 and ERO1a, PERK and CHOP
trigger the upregulation of protein translation and protein oxida-
tion that, in the face of ongoing protein misfolding, represent a
worsening to the original toxic insult (Han et al., 2013; Marciniak
et al., 2004). Although recovery of protein translation is a neces-
sary part of the adaptive response to acute ER stress,
in situations of chronic stress, increased protein synthesis can
contribute to toxicity (Figure 2). Recovery of protein translation
is brought about by dephosphorylation of eIF2a by GADD34
(Marciniak et al., 2004), and so antagonism of GADD34 protects
cells from chronic ER-stress-induced cell death (Tsaytler et al.,
2011). In a murine model of medulloblastoma, loss of GADD34
increased eIF2a phosphorylation and promoted tumor growth,
invasiveness, and angiogenesis (Lin et al., 2011). Thismay reflect
the increased induction of VEGFA observed inmice lacking func-
tional GADD34.
Although mutation of the GADD34 gene is a rare event in
human carcinogenesis, there is increasing evidence that sup-
pression of the CHOP-GADD34 axis may be a tumor survival
mechanism. For example, in malignant mesothelioma, loss of
GADD34 expression correlates well with the degree of tumor
dedifferentiation and a worse prognosis (Dalton et al., 2013).
Reduced expression ofCHOP inmammary carcinoma,mediated
by the PERK-induced microRNA mir211, promotes tumor cell
survival (Chitnis et al., 2012), while attenuation of PERK-CHOP
signaling by overexpression of the DNAJ cochaperone p58IPK
enables malignant progression under conditions of nutrient limi-
tation (Huber et al., 2013). It therefore appears likely that, while
PERK-ATF4 signaling may promote tumor survival, the induction
of GADD34 may have broadly tumor-suppressive effects
(Figure 2). This hypothesis is testable, since Gadd34 null mice
are viable (Marciniak et al., 2004). It is noteworthy that, in addition
to GADD34, which is normally induced by ER stress, cells also
possess a constitutively expressed eIF2a phosphatase called
CReP. Recently, this has been shown to be downregulated in
cells deficient in the tumor suppressor PTEN (Zeng et al.,
2011). The resulting increase in phosphorylated eIF2a in these
cells leads to increased resistance to oxidative stress.
Tumor-Specific Mechanisms for the Induction
of Endoplasmic Stress
A number of mechanisms contribute to cancer-specific induc-
tion of the UPR. For example, deficiencies of the tumor sup-
pressors tuberous sclerosis complex (Tsc)-1 or Tsc2, which
negatively regulate mTORC1, cause ER stress through uncon-
trolled protein synthesis (Ozcan et al., 2008). Constitutive activa-
tion of the serine/threonine kinase mTORC1 is common to many
cancers and stimulates protein synthesis and cell growth. How-ever, mTORC1 activity is often also repressed by homeostatic
responses to features of the tumor microenvironment, such as
hypoxia and nutrient deprivation, to promote cancer cell survival
(Figure 4) (Brugarolas et al., 2004; Inoki et al., 2003). Recently, it
has been recognized that an important function of Tsc2 is to
enable the cell to regulate its rate of protein synthesis to match
the availability of lipids (Du¨vel et al., 2010). In the secretory
pathway, these two processes are intimately linked, since an
increased demand for ER protein flux triggers an IRE1-XBP1-
dependent expansion of ER membrane to accommodate more
folding proteins. Defects in mTORC1 signaling can render
hypoxic tumors dependent on exogenous desaturated lipids,
an essential nutrient for hypoxic Tsc2/ tumors (Young et al.,
2013). Lipid-deprived Tsc2/ cells experience an exaggerated
ER stress response because IRE-1 activation fails to trigger
adequate expansion of the ER (Young et al., 2013). When lipids
are limiting, this leads to ER stress-induced cell death that can
be blocked by inhibition of mTORC1 with rapamycin. This
phenomenon was also seen in kidney tumors arising in Tsc2+/
mice, as well as inmultiple cancer cell lines, suggesting that ther-
apies targeting lipid desaturation machinery might enhance ER
stress-induced cell death in a tumor-specific manner (Young
et al., 2013).
Frequently, transformed cells depend on the activation of
prosurvival pathways such as those mediated by the oncogene
Myc (reviewed in Dang, 2010), which enhance proliferation
through cell cycle deregulation and increased protein synthesis.
Increased protein load leads to activation of the UPR, which
promotes malignant transformation through PERK-mediated
cytoprotective autophagy. Limiting protein synthesis by genetic
manipulation abrogates UPR activation by Myc and attenu-
ates lymphomagenesis in a murine model (Hart et al., 2012).
Accordingly, PERK inhibition diminished the level of autophagy
accompanyingMyc activation, leading to reduced colony forma-
tion in vitro and decreasing tumor formation in vivo (Hart et al.,
2012).
In some situations, ER stress responses appear to be used as
antioncogenic mechanisms. In naevi of the skin, components of
the MAPK pathways are commonly dysregulated, but although
many naevi have oncogenic mutations, few develop into
malignant melanomas. Instead, they senesce through incom-
pletely understood mechanisms (Michaloglou et al., 2005).
Oncogenic mutations of HRAS have been shown to trigger the
UPR via activation of the AKT pathway (Denoyelle et al., 2006),
and while the link between AKT and ER stress is unclear, the
consequence of UPR activation is to induce senescence and
prevent transformation.
The Role of Endoplasmic Reticulum Stress in Tumor
Immunogenicity
In cancer, ER stress has the capacity to activate cells of the
adaptive immune system (Wheeler et al., 2008) and is sufficient
to trigger systemic inflammation by proteolytic activation of the
transcription factor CREBH at the ER membrane (Zhang et al.,
2006). ER stress in prostate cancer causes the release of proin-
flammatory cytokines such as IL6 and tumor necrosis factor a
(Mahadevan et al., 2010), the promoters of which contain func-
tional XBP1s binding sites (Martinon et al., 2010). These cyto-
kines not only stimulate inflammation but also have beenCancer Cell 25, May 12, 2014 ª2014 Elsevier Inc. 567
Figure 4. Regulation of Protein Synthesis in
Cancer
mTORC1 stimulates protein translation at multiple
levels. Release of eukaryotic initiation factor 4E
(eIF4E) from its inhibitory binding partner 4E-BP is
promoted by 4E-BP phosphorylation by mTORC1,
while phosphorylation of S6K leads to activation
of eIF4A and eIF4B. Tsc1/2 complex inhibits
mTORC1 in response to cues from the tumor
microenvironments, while mitogenic factors inhibit
Tsc1/2 via PI3-kinase/Akt and Ras/Erk pathways
to promoting protein synthesis and growth (re-
viewed in Mendoza et al., 2011). PERK and IRE1
limit protein synthesis and expand the ER capacity
to match ER protein folding to the rate to protein
synthesis. GADD34-induced recovery of protein
synthesis can have toxic consequences during
chronic stress and so may mediate tumor-sup-
pressive effects. When glucose is limiting, reduced
cytosolic ATP:AMP ratios trigger Tsc1/2 via
AMPK, while hypoxia activates Tsc1/2 via HIF-1
and REDD1. Anoxia (O2 % 0.02%) additionally
activates PERK in a HIF-1 independent manner,
further limiting translation via eIF2a phosphoryla-
tion. Both hypoxia and nutrient deprivation alter
cell metabolism, promoting aerobic glycolysis,
lactate utilization, and glutaminolysis (reviewed in
Dang, 2012).
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et al., 2004). Remarkably, ER stress appears to be transmissible
from cancer cells to cells of the immune system. When cultured
in media conditioned by murine cancer cells experiencing ER
stress, macrophages show activation of the UPR in a TLR-
dependent manner (Mahadevan et al., 2011). It is plausible that
this acquired UPR of macrophages might cause the release
of proinflammatory mediators and thus contribute to tumor
inflammation.
Cell surface expression of damage-associated molecular
patterns (DAMPs) offers novel targeting strategies for immuno-
genic killing of cancer cells. ER-stress-mediated cell surface
presentation of calreticulin has emerged as a DAMP of potential
importance in cancer (Garg et al., 2012; Obeid et al., 2007). For
example, it has been proposed as a mechanism for immune
surveillance of hyperploid cancer cells, which display consti-
tutive ER stress (Senovilla et al., 2012). It is interesting that
anthracycline chemotherapeutics efficiently induce calreticulin
translocation to the cell surface, causing tumor immunogenicity,
while knockdown of calreticulin prevents phagocytosis and568 Cancer Cell 25, May 12, 2014 ª2014 Elsevier Inc.antigen presentation by dendritic cells
(Obeid et al., 2007). In contrast, agents
such as cisplatin that do not cause reloc-
alization of calreticulin fail to elicit an
anticancer immune response. This thera-
peutic limitation can be rectified by the
coadministration of ER-stress-inducing
agents (Martins et al., 2011). The com-
bined insult of ER stress and excess
reactive oxygen species appears to be
required for translocation of calreticulin
in a PERK-dependent process (Garg
et al., 2012; Martins et al., 2011; Panare-
takis et al., 2009). Phosphorylation ofeIF2a is likely to mediate this effect, although one report
suggested this to be nonessential (Garg et al., 2012). Although
calreticulin appears to be a key molecule in this response, the
combination of reactive oxygen species and ER stress also
causes surface exposure of additional DAMPs, the relative
importance of which remains unexplored (Fucikova et al.,
2011; Garg et al., 2012).
Endoplasmic Reticulum Stress as a Therapeutic Target
The homeostatic mechanisms that maintain proteostasis are
now sufficiently well understood to be legitimate targets of novel
anticancer strategies. For example, the HSP90 family of chaper-
ones are required for the proper folding and stability of many
kinases and transcription factors involved in tumor survival,
and HSP90 inhibitors have already entered clinical trials. Many
of the agents developed to target cytosolic HSP90s appear
also to inhibit the ER localized homolog GRP94, but it is currently
unclear which of these two targets is the most important for
cancer cell toxicity. Elevated levels of GRP94 have been
observed in many cancers and have been associated with
Cancer Cell
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Reduction of GRP94 levels has been shown to augment the
toxicity of etoposide (Reddy et al., 1999) and actinomycin D
(Pan et al., 2009), while overexpression of GRP94 in breast
cancer promoted cell proliferation and migration (Dejeans
et al., 2012a). Inhibition of GRP94 within the ER lumen was first
achieved with the prototype HSP90 inhibitor geldanamycin.
This agent and many of its derivatives have been shown to
induce ER stress and cell death (Marcu et al., 2002). Recently,
agents displaying selectivity for GRP94 were developed but ap-
peared to be less toxic than nonspecific inhibitors of HSP90
(Duerfeldt et al., 2012); however, drug combinations that
maximize ER stress and proteotoxicity may prove to be more
effective. When combined with rapamycin, the HSP90 inhibitor
retaspimycin, or IPI-504, caused catastrophic ER stress and
the regression of aggressive ras-driven tumors (De Raedt
et al., 2011). Since inhibition of HSP90 induces a robust heat
shock response through effects on cytosolic protein folding,
cytoprotective induction of cytosolic HSP70-class chaperones
is characteristically seen. Consequently, cells depleted of both
HSC70 and HSP72 show enhanced toxicity during inhibition of
HSP90 (Powers et al., 2008), offering further opportunities for
synergistic drug combinations.
Prolonged inhibition of HSP90 may also disable the cell’s
ability to mount a cytoprotective UPR, since PERK and IRE1
are stabilized by this chaperone (Marcu et al., 2002). These ER
stress sensors have been targets of a number of successful
small molecule inhibitor screening programs. The specific
PERK inhibitor GSK2656157 reduces cancer growth in vivo,
most likely via impaired angiogenesis and amino acid meta-
bolism (Atkins et al., 2013), while the inhibitors of IRE1, MKC-
3946 and STF-083010, both show antimyeloma activity in animal
models (Mimura et al., 2012; Papandreou et al., 2011). While it
has been noted that oncolytic viral therapy induces a prosurvival
UPR, the cytoprotective effects of this are diminished by inhibi-
tion of IRE1, leading to increased oncolytic efficacy (Mahoney
et al., 2011). This represents one of many potential utilities of
such compounds in combination therapies. It should be noted,
however, that agents that antagonize the UPR, such as PERK
inhibitors, are likely to cause some systemic toxicity, since con-
ditional ablation of PERK in the adult murine pancreas causes
diabetes through ER stress-induced b-cell death (Gao
et al., 2012). In addition, administration of the PERK inhibitor
GSK2656157 to mice for 2 weeks caused combined degenera-
tion of the endocrine and exocrine components of the pancreas
(Atkins et al., 2013). Following this brief treatment, the effects
appeared to be reversible on withdrawal of the drug, but longer
term effects have yet to be determined.
The proteasome inhibitor bortezomib can induce cell death in
Burkitt lymphoma (Shirley et al., 2011) and multiple myeloma
(Meister et al., 2007), at least in part via ER stress. It is likely
the highly secretory nature of myeloma cells that renders them
especially vulnerable to agents that promote ER stress, and
in vitro studies have shown that inhibition of the proteasome
synergizes with other therapies that increase the load of ER
misfolded proteins, such as photodynamic therapy (Szokalska
et al., 2009). In addition, bortezomib has been shown to kill
hypoxic tumor cells, preferentially through overactivation of the
UPR, since hypoxia is a cause of protein misfolding (Fels et al.,2008). The relative selectivity of bortezomib for a subset of
cancer cells reflects the dependence of professional secretory
cells on their ability to degrade proteins that have terminally
misfolded within the ER; the process of ER-associated degrada-
tion (ERAD). In addition to direct inhibition of the proteasome,
ERAD can be blocked by other means. Eeyarestatin I inhibits
the p97-Ufd1-Npl4 complex that mediates dislocation of polyu-
biquitinated substrates out of the ER into the cytosol and also
impairs their deubiquitination (Wang et al., 2008). This agent
synergizes with bortezomib in tumor cell killing by inducing the
proapoptotic protein NOXA in an ISR-dependent manner
(Wang et al., 2009). Similar synergy has been observed with
the combination of bortezomib and another p97 inhibitor,
DBeQ (Auner et al., 2013).
While the introduction of bortezomib has led to an increased
rate of remission in myeloma patients, acquired drug resistance
has limited its use in the clinic. Cells cultured in the presence of
proteasome inhibitors have been shown to acquire mutations of
the bortezomib binding site on proteasome subunit PSMB5 or to
overexpress this subunit, although such mutations are rarely
observed in the clinical setting (Balsas et al., 2012; Oerlemans
et al., 2008). An alternative mechanism involves increased basal
expression levels of BiP that allows cells to withstand the accu-
mulation of more misfolded proteins without activation of a cyto-
toxic UPR (Schewe and Aguirre-Ghiso, 2009). More recently, a
subpopulation of bortezomib-refractory B-cell progenitors has
been identified in which IRE1-XBP1s signaling is suppressed
(Leung-Hagesteijn et al., 2013). It has been known for some
time that XBP1s is necessary for the differentiation of B lympho-
cytes into plasma cells by enabling a dramatic expansion of the
ER (Carrasco et al., 2007). Continued signaling by the IRE1-
XBP1s axis was thought necessary to maintain healthy plasma
cells, but a recent screen identified IRE1 loss of function as pro-
moting bortezomib resistance in myeloma (Leung-Hagesteijn
et al., 2013). Despite previous evidence that inhibition of IRE1
is toxic to myeloma (Mimura et al., 2012; Papandreou et al.,
2011), knockdown of either IRE1 or XBP1 was surprisingly well
tolerated by myeloma-derived cell lines and induced resistance
to inhibition of the proteasome, while overexpression of XBP1s
restored sensitivity (Leung-Hagesteijn et al., 2013). Moreover,
XBP1 target genes were depressed in clinical samples from pro-
gressive myeloma. The protective effect of depleting myeloma
cells of XBP1s correlated with a partial reversal of plasma cell
differentiation, both morphologically and functionally, with a
reduced capacity to secrete immunoglobin light chains. More-
over, XBP1s-deficient myeloma progenitors could be isolated
from the bone marrow of patients with progressive disease,
and it was suggested that these represent a pool of cells intrinsi-
cally resistant to proteasome inhibition owing to their arrested
development. This may explain the inability of proteasome
inhibition to induce an outright cure in myeloma and the appear-
ance of resistance following initial remission. It is encouraging,
however, that bortezomib resistance can be overcome inmodels
of disease by potentiating the degree of ER stress with coadmin-
istration of an HSP90 inhibitor (Roue´ et al., 2011). The suppres-
sion of the UPR in some bortezomib-resistant cells is thought
to be facilitated by reduced phosphorylation of eIF2a. Accord-
ingly, promotion of phosph-eIF2a levels with the agent salubrinal
was shown to enhance bortezomib-induced cell killing (ScheweCancer Cell 25, May 12, 2014 ª2014 Elsevier Inc. 569
Figure 5. The UPR in Cancer
Activation of the UPR in malignancy results in complex signaling that is neither fully oncogenic nor tumor suppressive. The relative importance of each down-
stream pathway varies between cells depending on the chronicity of ER stress and on the relative expression of key factors; for example, GADD34. High rates of
protein synthesis during ER stress lead to cell death through the accumulation of misfolded protein, which would reduce tumormass. Loss of GADD34may serve
to antagonize this, leaving PERK unhindered in the attenuation of protein synthesis. Generation of ROS during ER stress, while potentially toxic, may help limit
tumor growth to match nutrient supply by initiating DNA damage checkpoints. Excess toxicity from ROS is limited by ATF4-mediated induction of antioxidant
pathways. Nutrient limitation within tumors is antagonized by autophagy and angiogenesis, which are induced by the PERK and IRE1 arms of the UPR. Reduced
expression of extracellular matrix molecules, such as BM-40, may limit migration and invasion.
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Reviewand Aguirre-Ghiso, 2009). Conversely, it has also been sug-
gested that enhanced induction of ATF4 may have undesirable
effects in the treatment of myeloma. Inhibition of the proteasome
is associated with accumulation of the antiapoptotic protein
Mcl-1, which can confer resistance to bortezomib (Hu et al.,
2012). This accumulation does not reflect stabilization of the
protein; instead, Mcl-1 appears to be induced by ATF4. Newer,
more selective inhibitors of eIF2a phosphatases are under devel-
opment and should help to clarify which effect, cytotoxicity or
antiapoptotic, is dominant.
Concluding Remarks
Current understanding of the cellular responses to ER stress has
made this a valid target for the development of rational therapies,
but the role of the UPR in modulating many aspects of tumor
behavior from cell proliferation and death to angiogenesis and in-
vasion is becoming clearer (Figure 5). It is perhaps not surprising
that the cellular response to ER stress is neither fully oncogenic
nor completely tumor suppressive. For example, antioxidant
pathways induced downstream of ATF4 appear to promote
tumor survival and may largely account for the requirement for570 Cancer Cell 25, May 12, 2014 ª2014 Elsevier Inc.PERK in models of solid tumors; while induction of GADD34
may be toxic to cancers experiencing chronic ER stress. Such
insights will contribute to better targeting of therapies while
also informing our appreciation of the cell biology of physiolog-
ical ER stress. Remarkably, the precise mechanisms of cell
death during ER stress remain unclear, and so better under-
standing will be required if death pathways are to be invoked
with selectivity to ER-stressed cancer cells. It is likely that the
relative importance of these death pathways will depend both
on the cancer type and on the tumor microenvironment, which
will offer further possibilities for personalization of treatment.
Finally, it is important to bear in mind the heterogeneity of
cancer as a disease, or rather as a group of diseases. The evo-
lution of an individual tumor over time frequently leads to loss
of differentiation and increased propensities for invasion and
metastasis, which will affect secretory capacity and reliance on
the UPR. Also, there is heterogeneity between subtypes of
cancer originating from a single tissue type such the breast,
which include basal-like, luminal-like, normal breast-like, and
HER2 positive. Given that subtype-dependent differences will
lead to differences in metabolic characteristics, it is to be
Cancer Cell
Reviewexpected that the importance of ER protein homeostasis for
each subtype will vary accordingly. This has already been
demonstrated in the context of cytosolic protein folding. HER2
is a client protein of Hsp90, and so HER2-positive tumors are
especially sensitive to inhibition of HSP90 (Rodrigues et al.,
2012). The highly secretory natures of the rare mucinous and
secretory breast cancers make them likely candidates for UPR
dependence.
A number of areas require further study. Clearly, there is a
need for a more sophisticated appreciation of the oncogenic
and tumor-suppressive features of the UPR. This is well illus-
trated by the antagonism of IRE1 that, while attenuating
tumor growth through impaired angiogenesis, might promote
tumor invasion. It is unclear what role the mutational burden
of a tumor cell plays in the induction of ER stress. Are specific
mutations more likely to cause ER stress? A better understand-
ing of how the UPR influences chemo- and radiosensitivity may
also direct more effective interventions.
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